ERBB2 and breast cancer: On the other hand, a meta-analysis of 636,535 patients indicated that the proportion of the HER2-low was higher in HR-positive than HR-negative breast cancer (67.5% vs. 48.6%) (Ergun, Ucar & Akagunduz, 2023).